The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy
Identifieur interne : 000E83 ( Istex/Corpus ); précédent : 000E82; suivant : 000E84The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy
Auteurs : Lionel Apetoh ; François Ghiringhelli ; Antoine Tesniere ; Alfredo Criollo ; Carla Ortiz ; Rosette Lidereau ; Christophe Mariette ; Nathalie Chaput ; Jean-Paul Mira ; Suzette Delaloge ; Fabrice André ; Thomas Tursz ; Guido Kroemer ; Laurence ZitvogelSource :
- Immunological Reviews [ 0105-2896 ] ; 2007-12.
Url:
DOI: 10.1111/j.1600-065X.2007.00573.x
Links to Exploration step
ISTEX:6E58E70BE60E9987B65A592E6DD568CE0C05FFEDLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy</title><author><name sortKey="Apetoh, Lionel" sort="Apetoh, Lionel" uniqKey="Apetoh L" first="Lionel" last="Apetoh">Lionel Apetoh</name><affiliation><mods:affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</mods:affiliation></affiliation></author><author><name sortKey="Ghiringhelli, Francois" sort="Ghiringhelli, Francois" uniqKey="Ghiringhelli F" first="François" last="Ghiringhelli">François Ghiringhelli</name><affiliation><mods:affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Centre d'Investigations Cliniques Biothérapies CBT507, IGR, Villejuif, France.</mods:affiliation></affiliation></author><author><name sortKey="Tesniere, Antoine" sort="Tesniere, Antoine" uniqKey="Tesniere A" first="Antoine" last="Tesniere">Antoine Tesniere</name><affiliation><mods:affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Institut National de la Santé et de la Recherche Médicale, U848 “Apoptosis, Cancer and Immunity,” Villejuif, France.</mods:affiliation></affiliation></author><author><name sortKey="Criollo, Alfredo" sort="Criollo, Alfredo" uniqKey="Criollo A" first="Alfredo" last="Criollo">Alfredo Criollo</name><affiliation><mods:affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Institut National de la Santé et de la Recherche Médicale, U848 “Apoptosis, Cancer and Immunity,” Villejuif, France.</mods:affiliation></affiliation></author><author><name sortKey="Ortiz, Carla" sort="Ortiz, Carla" uniqKey="Ortiz C" first="Carla" last="Ortiz">Carla Ortiz</name><affiliation><mods:affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</mods:affiliation></affiliation></author><author><name sortKey="Lidereau, Rosette" sort="Lidereau, Rosette" uniqKey="Lidereau R" first="Rosette" last="Lidereau">Rosette Lidereau</name><affiliation><mods:affiliation>Centre René Huguenin, FNCLCC, Institut National de la Santé et de la Recherche Médicale U735, St Cloud, France.</mods:affiliation></affiliation></author><author><name sortKey="Mariette, Christophe" sort="Mariette, Christophe" uniqKey="Mariette C" first="Christophe" last="Mariette">Christophe Mariette</name><affiliation><mods:affiliation>Centre Hospitalier Régional Universitaire de Lille, Laboratoire de Biochimie et de Biologie Moléculaire, Lille, France.</mods:affiliation></affiliation></author><author><name sortKey="Chaput, Nathalie" sort="Chaput, Nathalie" uniqKey="Chaput N" first="Nathalie" last="Chaput">Nathalie Chaput</name><affiliation><mods:affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Centre d'Investigations Cliniques Biothérapies CBT507, IGR, Villejuif, France.</mods:affiliation></affiliation></author><author><name sortKey="Mira, Jean Aul" sort="Mira, Jean Aul" uniqKey="Mira J" first="Jean-Paul" last="Mira">Jean-Paul Mira</name><affiliation><mods:affiliation>Institut Cochin, Département de Biologie Cellulaire, Institut National de la Santé et de la Recherche Médicale, U567, CNRS, UMR 8104, Université Paris‐Descartes, Faculté de Médecine René Descartes, Paris, France.</mods:affiliation></affiliation></author><author><name sortKey="Delaloge, Suzette" sort="Delaloge, Suzette" uniqKey="Delaloge S" first="Suzette" last="Delaloge">Suzette Delaloge</name><affiliation><mods:affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Medecine, Institut Gustave Roussy, Villejuif, France.</mods:affiliation></affiliation></author><author><name sortKey="Andre, Fabrice" sort="Andre, Fabrice" uniqKey="Andre F" first="Fabrice" last="André">Fabrice André</name><affiliation><mods:affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Medecine, Institut Gustave Roussy, Villejuif, France.</mods:affiliation></affiliation></author><author><name sortKey="Tursz, Thomas" sort="Tursz, Thomas" uniqKey="Tursz T" first="Thomas" last="Tursz">Thomas Tursz</name><affiliation><mods:affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Medecine, Institut Gustave Roussy, Villejuif, France.</mods:affiliation></affiliation></author><author><name sortKey="Kroemer, Guido" sort="Kroemer, Guido" uniqKey="Kroemer G" first="Guido" last="Kroemer">Guido Kroemer</name><affiliation><mods:affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Institut National de la Santé et de la Recherche Médicale, U848 “Apoptosis, Cancer and Immunity,” Villejuif, France.</mods:affiliation></affiliation></author><author><name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name><affiliation><mods:affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Centre d'Investigations Cliniques Biothérapies CBT507, IGR, Villejuif, France.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6E58E70BE60E9987B65A592E6DD568CE0C05FFED</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1111/j.1600-065X.2007.00573.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-F6NC73K3-P/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000E83</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000E83</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy</title><author><name sortKey="Apetoh, Lionel" sort="Apetoh, Lionel" uniqKey="Apetoh L" first="Lionel" last="Apetoh">Lionel Apetoh</name><affiliation><mods:affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</mods:affiliation></affiliation></author><author><name sortKey="Ghiringhelli, Francois" sort="Ghiringhelli, Francois" uniqKey="Ghiringhelli F" first="François" last="Ghiringhelli">François Ghiringhelli</name><affiliation><mods:affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Centre d'Investigations Cliniques Biothérapies CBT507, IGR, Villejuif, France.</mods:affiliation></affiliation></author><author><name sortKey="Tesniere, Antoine" sort="Tesniere, Antoine" uniqKey="Tesniere A" first="Antoine" last="Tesniere">Antoine Tesniere</name><affiliation><mods:affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Institut National de la Santé et de la Recherche Médicale, U848 “Apoptosis, Cancer and Immunity,” Villejuif, France.</mods:affiliation></affiliation></author><author><name sortKey="Criollo, Alfredo" sort="Criollo, Alfredo" uniqKey="Criollo A" first="Alfredo" last="Criollo">Alfredo Criollo</name><affiliation><mods:affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Institut National de la Santé et de la Recherche Médicale, U848 “Apoptosis, Cancer and Immunity,” Villejuif, France.</mods:affiliation></affiliation></author><author><name sortKey="Ortiz, Carla" sort="Ortiz, Carla" uniqKey="Ortiz C" first="Carla" last="Ortiz">Carla Ortiz</name><affiliation><mods:affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</mods:affiliation></affiliation></author><author><name sortKey="Lidereau, Rosette" sort="Lidereau, Rosette" uniqKey="Lidereau R" first="Rosette" last="Lidereau">Rosette Lidereau</name><affiliation><mods:affiliation>Centre René Huguenin, FNCLCC, Institut National de la Santé et de la Recherche Médicale U735, St Cloud, France.</mods:affiliation></affiliation></author><author><name sortKey="Mariette, Christophe" sort="Mariette, Christophe" uniqKey="Mariette C" first="Christophe" last="Mariette">Christophe Mariette</name><affiliation><mods:affiliation>Centre Hospitalier Régional Universitaire de Lille, Laboratoire de Biochimie et de Biologie Moléculaire, Lille, France.</mods:affiliation></affiliation></author><author><name sortKey="Chaput, Nathalie" sort="Chaput, Nathalie" uniqKey="Chaput N" first="Nathalie" last="Chaput">Nathalie Chaput</name><affiliation><mods:affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Centre d'Investigations Cliniques Biothérapies CBT507, IGR, Villejuif, France.</mods:affiliation></affiliation></author><author><name sortKey="Mira, Jean Aul" sort="Mira, Jean Aul" uniqKey="Mira J" first="Jean-Paul" last="Mira">Jean-Paul Mira</name><affiliation><mods:affiliation>Institut Cochin, Département de Biologie Cellulaire, Institut National de la Santé et de la Recherche Médicale, U567, CNRS, UMR 8104, Université Paris‐Descartes, Faculté de Médecine René Descartes, Paris, France.</mods:affiliation></affiliation></author><author><name sortKey="Delaloge, Suzette" sort="Delaloge, Suzette" uniqKey="Delaloge S" first="Suzette" last="Delaloge">Suzette Delaloge</name><affiliation><mods:affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Medecine, Institut Gustave Roussy, Villejuif, France.</mods:affiliation></affiliation></author><author><name sortKey="Andre, Fabrice" sort="Andre, Fabrice" uniqKey="Andre F" first="Fabrice" last="André">Fabrice André</name><affiliation><mods:affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Medecine, Institut Gustave Roussy, Villejuif, France.</mods:affiliation></affiliation></author><author><name sortKey="Tursz, Thomas" sort="Tursz, Thomas" uniqKey="Tursz T" first="Thomas" last="Tursz">Thomas Tursz</name><affiliation><mods:affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Medecine, Institut Gustave Roussy, Villejuif, France.</mods:affiliation></affiliation></author><author><name sortKey="Kroemer, Guido" sort="Kroemer, Guido" uniqKey="Kroemer G" first="Guido" last="Kroemer">Guido Kroemer</name><affiliation><mods:affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Institut National de la Santé et de la Recherche Médicale, U848 “Apoptosis, Cancer and Immunity,” Villejuif, France.</mods:affiliation></affiliation></author><author><name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name><affiliation><mods:affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</mods:affiliation></affiliation><affiliation><mods:affiliation>Centre d'Investigations Cliniques Biothérapies CBT507, IGR, Villejuif, France.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Immunological Reviews</title><title level="j" type="alt">IMMUNOLOGICAL REVIEWS</title><idno type="ISSN">0105-2896</idno><idno type="eISSN">1600-065X</idno><imprint><biblScope unit="vol">220</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="47">47</biblScope><biblScope unit="page" to="59">59</biblScope><biblScope unit="page-count">13</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2007-12">2007-12</date></imprint><idno type="ISSN">0105-2896</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0105-2896</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>tlr4</json:string><json:string>hmgb1</json:string><json:string>receptor</json:string><json:string>immune</json:string><json:string>chemotherapy</json:string><json:string>tumor cell</json:string><json:string>anticancer</json:string><json:string>immunol</json:string><json:string>dendritic</json:string><json:string>immunogenicity</json:string><json:string>apetoh</json:string><json:string>allele</json:string><json:string>immunological</json:string><json:string>radiotherapy</json:string><json:string>oxaliplatin</json:string><json:string>cytotoxic</json:string><json:string>polymorphism</json:string><json:string>mutation</json:string><json:string>nicotine</json:string><json:string>adjuvant</json:string><json:string>immune response</json:string><json:string>anticancer immunity</json:string><json:string>immunological review</json:string><json:string>dendritic cell</json:string><json:string>antitumor</json:string><json:string>cell death</json:string><json:string>chloroquine</json:string><json:string>immune system</json:string><json:string>immunosurveillance</json:string><json:string>tlr9</json:string><json:string>high mobility group</json:string><json:string>immunocompetent</json:string><json:string>node</json:string><json:string>macrophage</json:string><json:string>breast cancer patient</json:string><json:string>tlr4 mouse</json:string><json:string>tumor cell death</json:string><json:string>institut national</json:string><json:string>antigen presentation</json:string><json:string>ligand</json:string><json:string>datum</json:string><json:string>endogenous</json:string><json:string>tumor immunosurveillance</json:string><json:string>variant tlr4 allele</json:string><json:string>independent experiment</json:string><json:string>untreated</json:string><json:string>cognate immune response</json:string><json:string>host defense</json:string><json:string>single injection</json:string><json:string>similar result</json:string><json:string>glasgow osteosarcoma</json:string><json:string>tumor size</json:string><json:string>innate immunity</json:string><json:string>inflammatory response</json:string><json:string>tumor</json:string><json:string>institut</json:string></teeft></keywords><author><json:item><name>Lionel Apetoh</name><affiliations><json:string>Institut Gustave Roussy (IGR), Villejuif, France.</json:string><json:string>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</json:string><json:string>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</json:string></affiliations></json:item><json:item><name>François Ghiringhelli</name><affiliations><json:string>Institut Gustave Roussy (IGR), Villejuif, France.</json:string><json:string>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</json:string><json:string>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</json:string><json:string>Centre d'Investigations Cliniques Biothérapies CBT507, IGR, Villejuif, France.</json:string></affiliations></json:item><json:item><name>Antoine Tesniere</name><affiliations><json:string>Institut Gustave Roussy (IGR), Villejuif, France.</json:string><json:string>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</json:string><json:string>Institut National de la Santé et de la Recherche Médicale, U848 “Apoptosis, Cancer and Immunity,” Villejuif, France.</json:string></affiliations></json:item><json:item><name>Alfredo Criollo</name><affiliations><json:string>Institut Gustave Roussy (IGR), Villejuif, France.</json:string><json:string>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</json:string><json:string>Institut National de la Santé et de la Recherche Médicale, U848 “Apoptosis, Cancer and Immunity,” Villejuif, France.</json:string></affiliations></json:item><json:item><name>Carla Ortiz</name><affiliations><json:string>Institut Gustave Roussy (IGR), Villejuif, France.</json:string><json:string>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</json:string><json:string>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</json:string></affiliations></json:item><json:item><name>Rosette Lidereau</name><affiliations><json:string>Centre René Huguenin, FNCLCC, Institut National de la Santé et de la Recherche Médicale U735, St Cloud, France.</json:string></affiliations></json:item><json:item><name>Christophe Mariette</name><affiliations><json:string>Centre Hospitalier Régional Universitaire de Lille, Laboratoire de Biochimie et de Biologie Moléculaire, Lille, France.</json:string></affiliations></json:item><json:item><name>Nathalie Chaput</name><affiliations><json:string>Institut Gustave Roussy (IGR), Villejuif, France.</json:string><json:string>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</json:string><json:string>Centre d'Investigations Cliniques Biothérapies CBT507, IGR, Villejuif, France.</json:string></affiliations></json:item><json:item><name>Jean‐Paul Mira</name><affiliations><json:string>Institut Cochin, Département de Biologie Cellulaire, Institut National de la Santé et de la Recherche Médicale, U567, CNRS, UMR 8104, Université Paris‐Descartes, Faculté de Médecine René Descartes, Paris, France.</json:string></affiliations></json:item><json:item><name>Suzette Delaloge</name><affiliations><json:string>Institut Gustave Roussy (IGR), Villejuif, France.</json:string><json:string>Department of Medecine, Institut Gustave Roussy, Villejuif, France.</json:string></affiliations></json:item><json:item><name>Fabrice André</name><affiliations><json:string>Institut Gustave Roussy (IGR), Villejuif, France.</json:string><json:string>Department of Medecine, Institut Gustave Roussy, Villejuif, France.</json:string></affiliations></json:item><json:item><name>Thomas Tursz</name><affiliations><json:string>Institut Gustave Roussy (IGR), Villejuif, France.</json:string><json:string>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</json:string><json:string>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</json:string><json:string>Department of Medecine, Institut Gustave Roussy, Villejuif, France.</json:string></affiliations></json:item><json:item><name>Guido Kroemer</name><affiliations><json:string>Institut Gustave Roussy (IGR), Villejuif, France.</json:string><json:string>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</json:string><json:string>Institut National de la Santé et de la Recherche Médicale, U848 “Apoptosis, Cancer and Immunity,” Villejuif, France.</json:string></affiliations></json:item><json:item><name>Laurence Zitvogel</name><affiliations><json:string>Institut Gustave Roussy (IGR), Villejuif, France.</json:string><json:string>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</json:string><json:string>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</json:string><json:string>Centre d'Investigations Cliniques Biothérapies CBT507, IGR, Villejuif, France.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>TLR4</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>HMGB1</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dendritic cell</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>anti‐tumor vaccination</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>chemotherapy</value></json:item></subject><articleId><json:string>IMR573</json:string></articleId><arkIstex>ark:/67375/WNG-F6NC73K3-P</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>reviewArticle</json:string></originalGenre><qualityIndicators><score>7.012</score><pdfWordCount>6929</pdfWordCount><pdfCharCount>47176</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>13</pdfPageCount><pdfPageSize>595.276 x 782.362 pts</pdfPageSize><pdfWordsPerPage>533</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>1</abstractWordCount><abstractCharCount>0</abstractCharCount><keywordCount>5</keywordCount></qualityIndicators><title>The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy</title><pmid><json:string>17979839</json:string></pmid><genre><json:string>review-article</json:string></genre><host><title>Immunological Reviews</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1600-065X</json:string></doi><issn><json:string>0105-2896</json:string></issn><eissn><json:string>1600-065X</json:string></eissn><publisherId><json:string>IMR</json:string></publisherId><volume>220</volume><issue>1</issue><pages><first>47</first><last>59</last><total>13</total></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2007</json:string><json:string>1955</json:string><json:string>during the 20th century</json:string></date><geogName></geogName><orgName><json:string>National Cancer Institute</json:string><json:string>-France, and Association</json:string><json:string>Villejuif France Tel</json:string><json:string>NCI</json:string><json:string>Ligue</json:string><json:string>European Commission</json:string></orgName><orgName_funder><json:string>Ligue</json:string><json:string>European Commission</json:string></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Carla Ortiz</json:string><json:string>Christophe Mariette</json:string><json:string>Lionel Apetoh</json:string><json:string>Paris Sud-Universit</json:string><json:string>Francois Ghiringhelli</json:string><json:string>Fabrice Andr</json:string><json:string>Laurence Zitvogel</json:string><json:string>Nathalie Chaput</json:string><json:string>Alfredo Criollo</json:string><json:string>Guido Kroemer</json:string><json:string>Jean-Paul Mira</json:string><json:string>Mira Suzette</json:string><json:string>Rosette Lidereau</json:string><json:string>Suzette Delaloge</json:string><json:string>Mariette Nathalie</json:string><json:string>Antoine Tesniere</json:string><json:string>Gustave Roussy</json:string><json:string>Thomas Tursz</json:string></persName><placeName><json:string>Singapore</json:string><json:string>Immunogenicity</json:string><json:string>Glasgow</json:string><json:string>France</json:string><json:string>Lille</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Apetoh et al</json:string><json:string>Tian et al.</json:string><json:string>Apetoh et al.</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-F6NC73K3-P</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - immunology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - immunology</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - Immunology</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Immunology and Allergy</json:string></scopus></categories><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1111/j.1600-065X.2007.00573.x</json:string></doi><id>6E58E70BE60E9987B65A592E6DD568CE0C05FFED</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-F6NC73K3-P/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-F6NC73K3-P/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-F6NC73K3-P/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy</title><title level="a" type="short">TLR4 and HMGB1 in anticancer immunity</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2007-12"></date></publicationStmt><notesStmt><note type="content-type" subtype="review-article" source="reviewArticle" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="review-article"><analytic><title level="a" type="main">The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy</title><title level="a" type="short">TLR4 and HMGB1 in anticancer immunity</title><author xml:id="author-0000"><persName><forename type="first">Lionel</forename><surname>Apetoh</surname></persName><affiliation><orgName type="institution">Institut Gustave Roussy (IGR)</orgName><address><addrLine>Villejuif</addrLine><addrLine>France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation><affiliation><orgName type="institution">Faculté Paris Sud‐Université Paris XI</orgName><address><addrLine>Kremlin Bicêtre</addrLine><addrLine>France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation><affiliation><orgName type="institution">Institut National de la Santé et de la Recherche Médicale</orgName><address><addrLine>U805 “Immunologie et immunothérapie des tumeurs</addrLine><addrLine>” Villejuif, France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">François</forename><surname>Ghiringhelli</surname></persName><affiliation><orgName type="institution">Institut Gustave Roussy (IGR)</orgName><address><addrLine>Villejuif</addrLine><addrLine>France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation><affiliation><orgName type="institution">Faculté Paris Sud‐Université Paris XI</orgName><address><addrLine>Kremlin Bicêtre</addrLine><addrLine>France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation><affiliation><orgName type="institution">Institut National de la Santé et de la Recherche Médicale</orgName><address><addrLine>U805 “Immunologie et immunothérapie des tumeurs</addrLine><addrLine>” Villejuif, France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation><affiliation><orgName type="division">Centre d'Investigations Cliniques Biothérapies CBT507</orgName><address><addrLine>IGR</addrLine><addrLine>Villejuif, France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">Antoine</forename><surname>Tesniere</surname></persName><affiliation><orgName type="institution">Institut Gustave Roussy (IGR)</orgName><address><addrLine>Villejuif</addrLine><addrLine>France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation><affiliation><orgName type="institution">Faculté Paris Sud‐Université Paris XI</orgName><address><addrLine>Kremlin Bicêtre</addrLine><addrLine>France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation><affiliation><orgName type="institution">Institut National de la Santé et de la Recherche Médicale</orgName><address><addrLine>U848 “Apoptosis</addrLine><addrLine>Cancer and Immunity,” Villejuif, France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">Alfredo</forename><surname>Criollo</surname></persName><affiliation><orgName type="institution">Institut Gustave Roussy (IGR)</orgName><address><addrLine>Villejuif</addrLine><addrLine>France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation><affiliation><orgName type="institution">Faculté Paris Sud‐Université Paris XI</orgName><address><addrLine>Kremlin Bicêtre</addrLine><addrLine>France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation><affiliation><orgName type="institution">Institut National de la Santé et de la Recherche Médicale</orgName><address><addrLine>U848 “Apoptosis</addrLine><addrLine>Cancer and Immunity,” Villejuif, France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">Carla</forename><surname>Ortiz</surname></persName><affiliation><orgName type="institution">Institut Gustave Roussy (IGR)</orgName><address><addrLine>Villejuif</addrLine><addrLine>France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation><affiliation><orgName type="institution">Faculté Paris Sud‐Université Paris XI</orgName><address><addrLine>Kremlin Bicêtre</addrLine><addrLine>France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation><affiliation><orgName type="institution">Institut National de la Santé et de la Recherche Médicale</orgName><address><addrLine>U805 “Immunologie et immunothérapie des tumeurs</addrLine><addrLine>” Villejuif, France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation></author><author xml:id="author-0005"><persName><forename type="first">Rosette</forename><surname>Lidereau</surname></persName><affiliation><orgName type="division">Centre René Huguenin</orgName><address><addrLine>FNCLCC</addrLine><addrLine>Institut National de la Santé et de la Recherche Médicale U735, St Cloud, France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation></author><author xml:id="author-0006"><persName><forename type="first">Christophe</forename><surname>Mariette</surname></persName><affiliation><orgName type="institution">Centre Hospitalier Régional Universitaire de Lille</orgName><orgName type="laboratory">Laboratoire de Biochimie et de Biologie Moléculaire</orgName><address><addrLine>Lille</addrLine><addrLine>France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation></author><author xml:id="author-0007"><persName><forename type="first">Nathalie</forename><surname>Chaput</surname></persName><affiliation><orgName type="institution">Institut Gustave Roussy (IGR)</orgName><address><addrLine>Villejuif</addrLine><addrLine>France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation><affiliation><orgName type="institution">Institut National de la Santé et de la Recherche Médicale</orgName><address><addrLine>U805 “Immunologie et immunothérapie des tumeurs</addrLine><addrLine>” Villejuif, France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation><affiliation><orgName type="division">Centre d'Investigations Cliniques Biothérapies CBT507</orgName><address><addrLine>IGR</addrLine><addrLine>Villejuif, France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation></author><author xml:id="author-0008"><persName><forename type="first">Jean‐Paul</forename><surname>Mira</surname></persName><affiliation><orgName type="institution">Institut Cochin</orgName><orgName type="laboratory">Département de Biologie Cellulaire</orgName><orgName type="institution">Institut National de la Santé et de la Recherche Médicale</orgName><address><addrLine>U567</addrLine><addrLine>CNRS, UMR 8104, Université Paris‐Descartes, Faculté de Médecine René Descartes, Paris, France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation></author><author xml:id="author-0009"><persName><forename type="first">Suzette</forename><surname>Delaloge</surname></persName><affiliation><orgName type="institution">Institut Gustave Roussy (IGR)</orgName><address><addrLine>Villejuif</addrLine><addrLine>France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation><affiliation><orgName type="division">Department of Medecine</orgName><orgName type="institution">Institut Gustave Roussy</orgName><address><addrLine>Villejuif</addrLine><addrLine>France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation></author><author xml:id="author-0010"><persName><forename type="first">Fabrice</forename><surname>André</surname></persName><affiliation><orgName type="institution">Institut Gustave Roussy (IGR)</orgName><address><addrLine>Villejuif</addrLine><addrLine>France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation><affiliation><orgName type="division">Department of Medecine</orgName><orgName type="institution">Institut Gustave Roussy</orgName><address><addrLine>Villejuif</addrLine><addrLine>France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation></author><author xml:id="author-0011"><persName><forename type="first">Thomas</forename><surname>Tursz</surname></persName><affiliation><orgName type="institution">Institut Gustave Roussy (IGR)</orgName><address><addrLine>Villejuif</addrLine><addrLine>France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation><affiliation><orgName type="institution">Faculté Paris Sud‐Université Paris XI</orgName><address><addrLine>Kremlin Bicêtre</addrLine><addrLine>France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation><affiliation><orgName type="institution">Institut National de la Santé et de la Recherche Médicale</orgName><address><addrLine>U805 “Immunologie et immunothérapie des tumeurs</addrLine><addrLine>” Villejuif, France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation><affiliation><orgName type="division">Department of Medecine</orgName><orgName type="institution">Institut Gustave Roussy</orgName><address><addrLine>Villejuif</addrLine><addrLine>France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation></author><author xml:id="author-0012"><persName><forename type="first">Guido</forename><surname>Kroemer</surname></persName><affiliation><orgName type="institution">Institut Gustave Roussy (IGR)</orgName><address><addrLine>Villejuif</addrLine><addrLine>France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation><affiliation><orgName type="institution">Faculté Paris Sud‐Université Paris XI</orgName><address><addrLine>Kremlin Bicêtre</addrLine><addrLine>France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation><affiliation><orgName type="institution">Institut National de la Santé et de la Recherche Médicale</orgName><address><addrLine>U848 “Apoptosis</addrLine><addrLine>Cancer and Immunity,” Villejuif, France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation></author><author xml:id="author-0013"><persName><forename type="first">Laurence</forename><surname>Zitvogel</surname></persName><affiliation><orgName type="institution">Institut Gustave Roussy (IGR)</orgName><address><addrLine>Villejuif</addrLine><addrLine>France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation><affiliation><orgName type="institution">Faculté Paris Sud‐Université Paris XI</orgName><address><addrLine>Kremlin Bicêtre</addrLine><addrLine>France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation><affiliation><orgName type="institution">Institut National de la Santé et de la Recherche Médicale</orgName><address><addrLine>U805 “Immunologie et immunothérapie des tumeurs</addrLine><addrLine>” Villejuif, France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation><affiliation><orgName type="division">Centre d'Investigations Cliniques Biothérapies CBT507</orgName><address><addrLine>IGR</addrLine><addrLine>Villejuif, France.</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation></author><idno type="istex">6E58E70BE60E9987B65A592E6DD568CE0C05FFED</idno><idno type="ark">ark:/67375/WNG-F6NC73K3-P</idno><idno type="DOI">10.1111/j.1600-065X.2007.00573.x</idno><idno type="unit">IMR573</idno><idno type="supplier">573</idno><idno type="toTypesetVersion">file:IMR.IMR573.pdf</idno></analytic><monogr><title level="j" type="main">Immunological Reviews</title><title level="j" type="alt">IMMUNOLOGICAL REVIEWS</title><idno type="pISSN">0105-2896</idno><idno type="eISSN">1600-065X</idno><idno type="book-DOI">10.1111/(ISSN)1600-065X</idno><idno type="book-part-DOI">10.1111/imr.2007.220.issue-1</idno><idno type="product">IMR</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">220</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="47">47</biblScope><biblScope unit="page" to="59">59</biblScope><biblScope unit="page-count">13</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2007-12"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><p><hi rend="bold">Summary: </hi> For the last four decades, the treatment of cancer has relied on four treatment modalities, namely surgery, radiotherapy, cytotoxic chemotherapy, and hormonotherapy. Most of these therapies are believed to directly attack and eradicate tumor cells. The emerging concept that cancer is not just a disease of a tissue or an organ but also a host disease relies on evidence of tumor‐induced immunosuppression and polymorphisms in genes involved in host protection against tumors. This theory is now gaining new impetus, based on our recent data showing that optimal therapeutic effects require the immunoadjuvant effect of tumor cell death induced by cytotoxic anticancer agents. Here, we show that the release of the high mobility group box 1 protein (HMGB1) by dying tumor cells is mandatory to license host dendritic cells (DCs) to process and present tumor antigens. HMGB1 interacts with Toll‐like receptor 4 (TLR4) on DCs, which are selectively involved in the cross‐priming of anti‐tumor T lymphocytes <hi rend="italic">in vivo</hi>. A TLR4 polymorphism that affects the binding of HMGB1 to TLR4 predicts early relapse after anthracycline‐based chemotherapy in breast cancer patients. This knowledge may be clinically exploited to predict the immunogenicity and hence the efficacy of chemotherapeutic regimens.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="k1">TLR4</term><term xml:id="k2">HMGB1</term><term xml:id="k3">dendritic cell</term><term xml:id="k4">anti‐tumor vaccination</term><term xml:id="k5">chemotherapy</term></keywords><keywords rend="tocHeading1"><term>Review Articles</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-F6NC73K3-P/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1600-065X</doi><issn type="print">0105-2896</issn><issn type="electronic">1600-065X</issn><idGroup><id type="product" value="IMR"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="IMMUNOLOGICAL REVIEWS">Immunological Reviews</title></titleGroup></publicationMeta><publicationMeta level="part" position="12001"><doi origin="wiley">10.1111/imr.2007.220.issue-1</doi><numberingGroup><numbering type="journalVolume" number="220">220</numbering><numbering type="journalIssue" number="1">1</numbering></numberingGroup><coverDate startDate="2007-12">December 2007</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="5" status="forIssue"><doi origin="wiley">10.1111/j.1600-065X.2007.00573.x</doi><idGroup><id type="unit" value="IMR573"></id><id type="supplier" value="573"></id></idGroup><countGroup><count type="pageTotal" number="13"></count></countGroup><titleGroup><title type="tocHeading1">Review Articles</title></titleGroup><eventGroup><event type="firstOnline" date="2007-10-30"></event><event type="publishedOnlineFinalForm" date="2007-10-30"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-06"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-13"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-24"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="47">47</numbering><numbering type="pageLast" number="59">59</numbering></numberingGroup><correspondenceTo>
<i>Laurence Zitvogel</i>
U805 and CBT507 Institut National de la Santé et de la Recherche Médicale
Institut Gustave Roussy
39 rue Camille Desmoulins
F‐94805 Villejuif
France
Tel.: +33 1 42 11 50 41
Fax: +33 1 42 11 60 94
e‐mail: <email normalForm="zitvogel@igr.fr">zitvogel@igr.fr</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:IMR.IMR573.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="8"></count><count type="tableTotal" number="1"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="80"></count><count type="wordTotal" number="8852"></count><count type="linksCrossRef" number="140"></count></countGroup><titleGroup><title type="main">The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy</title><title type="shortAuthors">Apetoh et al</title><title type="short">TLR4 and HMGB1 in anticancer immunity</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1 #a2 #a3" noteRef="#fn1"><personName><givenNames>Lionel</givenNames><familyName>Apetoh</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a1 #a2 #a3 #a4" noteRef="#fn1"><personName><givenNames>François</givenNames><familyName>Ghiringhelli</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a1 #a2 #a5" noteRef="#fn1"><personName><givenNames>Antoine</givenNames><familyName>Tesniere</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a1 #a2 #a5"><personName><givenNames>Alfredo</givenNames><familyName>Criollo</familyName></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a1 #a2 #a3"><personName><givenNames>Carla</givenNames><familyName>Ortiz</familyName></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#a6"><personName><givenNames>Rosette</givenNames><familyName>Lidereau</familyName></personName></creator><creator creatorRole="author" xml:id="cr7" affiliationRef="#a7"><personName><givenNames>Christophe</givenNames><familyName>Mariette</familyName></personName></creator><creator creatorRole="author" xml:id="cr8" affiliationRef="#a1 #a3 #a4"><personName><givenNames>Nathalie</givenNames><familyName>Chaput</familyName></personName></creator><creator creatorRole="author" xml:id="cr9" affiliationRef="#a8"><personName><givenNames>Jean‐Paul</givenNames><familyName>Mira</familyName></personName></creator><creator creatorRole="author" xml:id="cr10" affiliationRef="#a1 #a9"><personName><givenNames>Suzette</givenNames><familyName>Delaloge</familyName></personName></creator><creator creatorRole="author" xml:id="cr11" affiliationRef="#a1 #a9"><personName><givenNames>Fabrice</givenNames><familyName>André</familyName></personName></creator><creator creatorRole="author" xml:id="cr12" affiliationRef="#a1 #a2 #a3 #a9"><personName><givenNames>Thomas</givenNames><familyName>Tursz</familyName></personName></creator><creator creatorRole="author" xml:id="cr13" affiliationRef="#a1 #a2 #a5" noteRef="#fn2"><personName><givenNames>Guido</givenNames><familyName>Kroemer</familyName></personName></creator><creator creatorRole="author" xml:id="cr14" affiliationRef="#a1 #a2 #a3 #a4" noteRef="#fn2"><personName><givenNames>Laurence</givenNames><familyName>Zitvogel</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="FR"><unparsedAffiliation>Institut Gustave Roussy (IGR), Villejuif, France.</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="FR"><unparsedAffiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</unparsedAffiliation></affiliation><affiliation xml:id="a3" countryCode="FR"><unparsedAffiliation>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</unparsedAffiliation></affiliation><affiliation xml:id="a4" countryCode="FR"><unparsedAffiliation>Centre d'Investigations Cliniques Biothérapies CBT507, IGR, Villejuif, France.</unparsedAffiliation></affiliation><affiliation xml:id="a5" countryCode="FR"><unparsedAffiliation>Institut National de la Santé et de la Recherche Médicale, U848 “Apoptosis, Cancer and Immunity,” Villejuif, France.</unparsedAffiliation></affiliation><affiliation xml:id="a6" countryCode="FR"><unparsedAffiliation>Centre René Huguenin, FNCLCC, Institut National de la Santé et de la Recherche Médicale U735, St Cloud, France.</unparsedAffiliation></affiliation><affiliation xml:id="a7" countryCode="FR"><unparsedAffiliation>Centre Hospitalier Régional Universitaire de Lille, Laboratoire de Biochimie et de Biologie Moléculaire, Lille, France.</unparsedAffiliation></affiliation><affiliation xml:id="a8" countryCode="FR"><unparsedAffiliation>Institut Cochin, Département de Biologie Cellulaire, Institut National de la Santé et de la Recherche Médicale, U567, CNRS, UMR 8104, Université Paris‐Descartes, Faculté de Médecine René Descartes, Paris, France.</unparsedAffiliation></affiliation><affiliation xml:id="a9" countryCode="FR"><unparsedAffiliation>Department of Medecine, Institut Gustave Roussy, Villejuif, France.</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">TLR4</keyword><keyword xml:id="k2">HMGB1</keyword><keyword xml:id="k3">dendritic cell</keyword><keyword xml:id="k4">anti‐tumor vaccination</keyword><keyword xml:id="k5">chemotherapy</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p><b>Summary: </b> For the last four decades, the treatment of cancer has relied on four treatment modalities, namely surgery, radiotherapy, cytotoxic chemotherapy, and hormonotherapy. Most of these therapies are believed to directly attack and eradicate tumor cells. The emerging concept that cancer is not just a disease of a tissue or an organ but also a host disease relies on evidence of tumor‐induced immunosuppression and polymorphisms in genes involved in host protection against tumors. This theory is now gaining new impetus, based on our recent data showing that optimal therapeutic effects require the immunoadjuvant effect of tumor cell death induced by cytotoxic anticancer agents. Here, we show that the release of the high mobility group box 1 protein (HMGB1) by dying tumor cells is mandatory to license host dendritic cells (DCs) to process and present tumor antigens. HMGB1 interacts with Toll‐like receptor 4 (TLR4) on DCs, which are selectively involved in the cross‐priming of anti‐tumor T lymphocytes <i>in vivo</i>. A TLR4 polymorphism that affects the binding of HMGB1 to TLR4 predicts early relapse after anthracycline‐based chemotherapy in breast cancer patients. This knowledge may be clinically exploited to predict the immunogenicity and hence the efficacy of chemotherapeutic regimens.</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1" numbered="no"><p><sup>*</sup>L.A., F.G. and A.T. share co‐authorship.</p></note><note xml:id="fn2" numbered="no"><p><sup>†</sup>L.Z. and G.K. share senior authorship.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>TLR4 and HMGB1 in anticancer immunity</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy</title></titleInfo><name type="personal"><namePart type="given">Lionel</namePart><namePart type="family">Apetoh</namePart><affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</affiliation><affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</affiliation><affiliation>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</affiliation><description>*L.A., F.G. and A.T. share co‐authorship.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">François</namePart><namePart type="family">Ghiringhelli</namePart><affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</affiliation><affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</affiliation><affiliation>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</affiliation><affiliation>Centre d'Investigations Cliniques Biothérapies CBT507, IGR, Villejuif, France.</affiliation><description>*L.A., F.G. and A.T. share co‐authorship.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Antoine</namePart><namePart type="family">Tesniere</namePart><affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</affiliation><affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</affiliation><affiliation>Institut National de la Santé et de la Recherche Médicale, U848 “Apoptosis, Cancer and Immunity,” Villejuif, France.</affiliation><description>*L.A., F.G. and A.T. share co‐authorship.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alfredo</namePart><namePart type="family">Criollo</namePart><affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</affiliation><affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</affiliation><affiliation>Institut National de la Santé et de la Recherche Médicale, U848 “Apoptosis, Cancer and Immunity,” Villejuif, France.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Carla</namePart><namePart type="family">Ortiz</namePart><affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</affiliation><affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</affiliation><affiliation>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Rosette</namePart><namePart type="family">Lidereau</namePart><affiliation>Centre René Huguenin, FNCLCC, Institut National de la Santé et de la Recherche Médicale U735, St Cloud, France.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christophe</namePart><namePart type="family">Mariette</namePart><affiliation>Centre Hospitalier Régional Universitaire de Lille, Laboratoire de Biochimie et de Biologie Moléculaire, Lille, France.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Nathalie</namePart><namePart type="family">Chaput</namePart><affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</affiliation><affiliation>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</affiliation><affiliation>Centre d'Investigations Cliniques Biothérapies CBT507, IGR, Villejuif, France.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jean‐Paul</namePart><namePart type="family">Mira</namePart><affiliation>Institut Cochin, Département de Biologie Cellulaire, Institut National de la Santé et de la Recherche Médicale, U567, CNRS, UMR 8104, Université Paris‐Descartes, Faculté de Médecine René Descartes, Paris, France.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Suzette</namePart><namePart type="family">Delaloge</namePart><affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</affiliation><affiliation>Department of Medecine, Institut Gustave Roussy, Villejuif, France.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Fabrice</namePart><namePart type="family">André</namePart><affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</affiliation><affiliation>Department of Medecine, Institut Gustave Roussy, Villejuif, France.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Thomas</namePart><namePart type="family">Tursz</namePart><affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</affiliation><affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</affiliation><affiliation>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</affiliation><affiliation>Department of Medecine, Institut Gustave Roussy, Villejuif, France.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Guido</namePart><namePart type="family">Kroemer</namePart><affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</affiliation><affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</affiliation><affiliation>Institut National de la Santé et de la Recherche Médicale, U848 “Apoptosis, Cancer and Immunity,” Villejuif, France.</affiliation><description>†L.Z. and G.K. share senior authorship.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Laurence</namePart><namePart type="family">Zitvogel</namePart><affiliation>Institut Gustave Roussy (IGR), Villejuif, France.</affiliation><affiliation>Faculté Paris Sud‐Université Paris XI, Kremlin Bicêtre, France.</affiliation><affiliation>Institut National de la Santé et de la Recherche Médicale, U805 “Immunologie et immunothérapie des tumeurs,” Villejuif, France.</affiliation><affiliation>Centre d'Investigations Cliniques Biothérapies CBT507, IGR, Villejuif, France.</affiliation><description>†L.Z. and G.K. share senior authorship.</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2007-12</dateIssued><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">8</extent><extent unit="tables">1</extent><extent unit="formulas">0</extent><extent unit="references">80</extent><extent unit="linksCrossRef">140</extent><extent unit="words">8852</extent></physicalDescription>Summary: For the last four decades, the treatment of cancer has relied on four treatment modalities, namely surgery, radiotherapy, cytotoxic chemotherapy, and hormonotherapy. Most of these therapies are believed to directly attack and eradicate tumor cells. The emerging concept that cancer is not just a disease of a tissue or an organ but also a host disease relies on evidence of tumor‐induced immunosuppression and polymorphisms in genes involved in host protection against tumors. This theory is now gaining new impetus, based on our recent data showing that optimal therapeutic effects require the immunoadjuvant effect of tumor cell death induced by cytotoxic anticancer agents. Here, we show that the release of the high mobility group box 1 protein (HMGB1) by dying tumor cells is mandatory to license host dendritic cells (DCs) to process and present tumor antigens. HMGB1 interacts with Toll‐like receptor 4 (TLR4) on DCs, which are selectively involved in the cross‐priming of anti‐tumor T lymphocytes in vivo. A TLR4 polymorphism that affects the binding of HMGB1 to TLR4 predicts early relapse after anthracycline‐based chemotherapy in breast cancer patients. This knowledge may be clinically exploited to predict the immunogenicity and hence the efficacy of chemotherapeutic regimens.<subject lang="en"><genre>keywords</genre><topic>TLR4</topic><topic>HMGB1</topic><topic>dendritic cell</topic><topic>anti‐tumor vaccination</topic><topic>chemotherapy</topic></subject><relatedItem type="host"><titleInfo><title>Immunological Reviews</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0105-2896</identifier><identifier type="eISSN">1600-065X</identifier><identifier type="DOI">10.1111/(ISSN)1600-065X</identifier><identifier type="PublisherID">IMR</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>220</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>47</start><end>59</end><total>13</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>Timeline</title></titleInfo><name type="personal"><namePart type="given">BA</namePart><namePart type="family">Chabner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TG</namePart><namePart type="family">Roberts Jr</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chabner BA, Roberts TG Jr. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer 2005;5:65–72.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>65</start><end>72</end></extent></part><relatedItem type="host"><titleInfo><title>chemotherapy and the war on cancer</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>65</start><end>72</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>Therapeutic targeting of innate immunity with toll‐like receptor agonists and antagonists</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Kanzler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FJ</namePart><namePart type="family">Barrat</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EM</namePart><namePart type="family">Hessel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RL</namePart><namePart type="family">Coffman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with toll‐like receptor agonists and antagonists. Nat Med 2007;13:552–559.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>552</start><end>559</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>552</start><end>559</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Cancer regression and autoimmunity induced by cytotoxic T lymphocyte‐associated antigen 4 blockade in patients with metastatic melanoma</title></titleInfo><name type="personal"><namePart type="given">GQ</namePart><namePart type="family">Phan</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Phan GQ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte‐associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003;100:8372–8377.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>8372</start><end>8377</end></extent></part><relatedItem type="host"><titleInfo><title>Proc Natl Acad Sci USA</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>8372</start><end>8377</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>Blockade of B7‐H1 and PD‐1 by monoclonal antibodies potentiates cancer therapeutic immunity</title></titleInfo><name type="personal"><namePart type="given">F</namePart><namePart type="family">Hirano</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hirano F, et al. Blockade of B7‐H1 and PD‐1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005;65:1089–1096.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>1089</start><end>1096</end></extent></part><relatedItem type="host"><titleInfo><title>Cancer Res</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>1089</start><end>1096</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>Dendritic cells as therapeutic vaccines against cancer</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Banchereau</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AK</namePart><namePart type="family">Palucka</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5:296–306.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>296</start><end>306</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Rev Immunol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>296</start><end>306</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Dendritic cells and the control of immunity</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Banchereau</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RM</namePart><namePart type="family">Steinman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245–252.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>392</number></detail><extent unit="pages"><start>245</start><end>252</end></extent></part><relatedItem type="host"><titleInfo><title>Nature</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>392</number></detail><extent unit="pages"><start>245</start><end>252</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>How the immune system works to protect the host from infection</title></titleInfo><name type="personal"><namePart type="given">CA</namePart><namePart type="family">Janeway Jr</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Janeway CA Jr. How the immune system works to protect the host from infection: a personal view. Proc Natl Acad Sci USA 2001;98:7461–7468.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>7461</start><end>7468</end></extent></part><relatedItem type="host"><titleInfo><title>a personal view</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>7461</start><end>7468</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>A human homologue of the Drosophila toll protein signals activation of adaptive immunity</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Medzhitov</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Preston‐Hurlburt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CA</namePart><namePart type="family">Janeway Jr</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Medzhitov R, Preston‐Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila toll protein signals activation of adaptive immunity. Nature 1997;388:394–397.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>388</number></detail><extent unit="pages"><start>394</start><end>397</end></extent></part><relatedItem type="host"><titleInfo><title>Nature</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>388</number></detail><extent unit="pages"><start>394</start><end>397</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>Innate immunity</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Medzhitov</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CA</namePart><namePart type="family">Janeway Jr</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Medzhitov R, Janeway CA Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997;91:295–298.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>91</number></detail><extent unit="pages"><start>295</start><end>298</end></extent></part><relatedItem type="host"><titleInfo><title>the virtues of a nonclonal system of recognition</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>91</number></detail><extent unit="pages"><start>295</start><end>298</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>Tolerance, danger, and the extended family</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">Matzinger</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991–1045.</note><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>991</start><end>1045</end></extent></part><relatedItem type="host"><titleInfo><title>Annu Rev Immunol</title></titleInfo><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>991</start><end>1045</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>Natural adjuvants</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Gallucci</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Lolkema</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Matzinger</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999;5:1249–1255.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>1249</start><end>1255</end></extent></part><relatedItem type="host"><titleInfo><title>endogenous activators of dendritic cells</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>1249</start><end>1255</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Major histocompatibility complex class I‐restricted cross‐presentation is biased towards high dose antigens and those released during cellular destruction</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Kurts</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JF</namePart><namePart type="family">Miller</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RM</namePart><namePart type="family">Subramaniam</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FR</namePart><namePart type="family">Carbone</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WR</namePart><namePart type="family">Heath</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kurts C, Miller JF, Subramaniam RM, Carbone FR, Heath WR. Major histocompatibility complex class I‐restricted cross‐presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 1998;188:409–414.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>188</number></detail><extent unit="pages"><start>409</start><end>414</end></extent></part><relatedItem type="host"><titleInfo><title>J Exp Med</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>188</number></detail><extent unit="pages"><start>409</start><end>414</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>Cell death releases endogenous adjuvants that selectively enhance immune surveillance of particulate antigens</title></titleInfo><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Shi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KL</namePart><namePart type="family">Rock</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shi Y, Rock KL. Cell death releases endogenous adjuvants that selectively enhance immune surveillance of particulate antigens. Eur J Immunol 2002;32:155–162.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>155</start><end>162</end></extent></part><relatedItem type="host"><titleInfo><title>Eur J Immunol</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>155</start><end>162</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll‐like receptors 3, 7 and 9</title></titleInfo><name type="personal"><namePart type="given">K</namePart><namePart type="family">Tabeta</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tabeta K, et al. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll‐like receptors 3, 7 and 9. Nat Immunol 2006;7:156–164.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>156</start><end>164</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Immunol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>156</start><end>164</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>Efficient T cell activation via a toll‐interleukin 1 receptor‐independent pathway</title></titleInfo><name type="personal"><namePart type="given">E</namePart><namePart type="family">Janssen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Janssen E, et al. Efficient T cell activation via a toll‐interleukin 1 receptor‐independent pathway. Immunity 2006;24:787–799.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>787</start><end>799</end></extent></part><relatedItem type="host"><titleInfo><title>Immunity</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>787</start><end>799</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Molecular identification of a danger signal that alerts the immune system to dying cells</title></titleInfo><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Shi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JE</namePart><namePart type="family">Evans</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KL</namePart><namePart type="family">Rock</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003;425:516–521.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>425</number></detail><extent unit="pages"><start>516</start><end>521</end></extent></part><relatedItem type="host"><titleInfo><title>Nature</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>425</number></detail><extent unit="pages"><start>516</start><end>521</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>Extracellular ATP induces a distorted maturation of dendritic cells and inhibits their capacity to initiate Th1 responses</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">La Sala</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Ferrari</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Corinti</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Cavani</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Di Virgilio</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Girolomoni</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">La Sala A, Ferrari D, Corinti S, Cavani A, Di Virgilio F, Girolomoni G. Extracellular ATP induces a distorted maturation of dendritic cells and inhibits their capacity to initiate Th1 responses. J Immunol 2001;166:1611–1617.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>166</number></detail><extent unit="pages"><start>1611</start><end>1617</end></extent></part><relatedItem type="host"><titleInfo><title>J Immunol</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>166</number></detail><extent unit="pages"><start>1611</start><end>1617</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit18"><titleInfo><title>Toll‐like receptors in systemic autoimmune disease</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Marshak‐Rothstein</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Marshak‐Rothstein A. Toll‐like receptors in systemic autoimmune disease. Nat Rev Immunol 2006;6:823–835.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>823</start><end>835</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Rev Immunol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>823</start><end>835</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit19"><titleInfo><title>Regulation of lung injury and repair by toll‐like receptors and hyaluronan</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Jiang</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jiang D, et al. Regulation of lung injury and repair by toll‐like receptors and hyaluronan. Nat Med 2005;11:1173–1179.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>1173</start><end>1179</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>1173</start><end>1179</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit20"><titleInfo><title>The national program for cancer chemotherapy</title></titleInfo><name type="personal"><namePart type="given">CG</namePart><namePart type="family">Zubrod</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zubrod CG. The national program for cancer chemotherapy. JAMA 1972;222:1161–1162.</note><part><date>1972</date><detail type="volume"><caption>vol.</caption><number>222</number></detail><extent unit="pages"><start>1161</start><end>1162</end></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>1972</date><detail type="volume"><caption>vol.</caption><number>222</number></detail><extent unit="pages"><start>1161</start><end>1162</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit21"><titleInfo><title>Johnson J, Monks A, Hollingshead M, Sausville EIn: Chabner BA, Longo D, eds. Cancer Chemotherapy and Biotherapy. Philadelphia: Lippincott Williams & Wilkins, 2001:17–36.</title></titleInfo><note type="citation/reference">Johnson J, Monks A, Hollingshead M, Sausville E In: Chabner BA, Longo D, eds. Cancer Chemotherapy and Biotherapy. Philadelphia: Lippincott Williams & Wilkins, 2001:17–36.</note><name type="personal"><namePart type="given">J</namePart><namePart type="family">Johnson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Monks</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Hollingshead</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Sausville</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BA</namePart><namePart type="family">Chabner</namePart><role><roleTerm type="text">editor</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Longo</namePart><role><roleTerm type="text">editor</roleTerm></role></name><genre>book</genre><originInfo><publisher>Lippincott Williams & Wilkins</publisher></originInfo><part><date>2001</date><extent unit="pages"><start>17</start><end>36</end></extent></part></relatedItem><relatedItem type="references" displayLabel="cit22"><titleInfo><title>Anticancer drug development at the US National Cancer Institute</title></titleInfo><name type="personal"><namePart type="given">CH</namePart><namePart type="family">Takimoto</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Takimoto CH. Anticancer drug development at the US National Cancer Institute. Cancer Chemother Pharmacol 2003;52 (Suppl.):S29–S33.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><detail type="issue"><caption>no.</caption><number>(Suppl.)</number></detail><extent unit="pages"><start>S29</start><end>S33</end></extent></part><relatedItem type="host"><titleInfo><title>Cancer Chemother Pharmacol</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><detail type="issue"><caption>no.</caption><number>(Suppl.)</number></detail><extent unit="pages"><start>S29</start><end>S33</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit23"><titleInfo><title>Of mice and men</title></titleInfo><name type="personal"><namePart type="given">LR</namePart><namePart type="family">Kelland</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kelland LR. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 2004;40:827–836.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>827</start><end>836</end></extent></part><relatedItem type="host"><titleInfo><title>values and liabilities of the athymic nude mouse model in anticancer drug development</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>827</start><end>836</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit24"><titleInfo><title>Caspase‐dependent immunogenicity of doxorubicin‐induced tumor cell death</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Casares</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Casares N, et al. Caspase‐dependent immunogenicity of doxorubicin‐induced tumor cell death. J Exp Med 2005;202:1691–1701.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>202</number></detail><extent unit="pages"><start>1691</start><end>1701</end></extent></part><relatedItem type="host"><titleInfo><title>J Exp Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>202</number></detail><extent unit="pages"><start>1691</start><end>1701</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit25"><titleInfo><title>Toll‐like receptor 4‐dependent contribution of the immune system to anticancer chemotherapy and radiotherapy</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Apetoh</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Apetoh L, et al. Toll‐like receptor 4‐dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050–1059.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>1050</start><end>1059</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>1050</start><end>1059</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit26"><titleInfo><title>Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma</title></titleInfo><name type="personal"><namePart type="given">TG</namePart><namePart type="family">Granda</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Granda TG, et al. Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. Br J Cancer 2002;86:999–1005.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>86</number></detail><extent unit="pages"><start>999</start><end>1005</end></extent></part><relatedItem type="host"><titleInfo><title>Br J Cancer</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>86</number></detail><extent unit="pages"><start>999</start><end>1005</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit27"><titleInfo><title>Toll‐like receptor 4 in butylated hydroxytoluene‐induced mouse pulmonary inflammation and tumorigenesis</title></titleInfo><name type="personal"><namePart type="given">AK</namePart><namePart type="family">Bauer</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bauer AK, et al. Toll‐like receptor 4 in butylated hydroxytoluene‐induced mouse pulmonary inflammation and tumorigenesis. J Natl Cancer Inst 2005;97:1778–1781.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>97</number></detail><extent unit="pages"><start>1778</start><end>1781</end></extent></part><relatedItem type="host"><titleInfo><title>J Natl Cancer Inst</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>97</number></detail><extent unit="pages"><start>1778</start><end>1781</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit28"><titleInfo><title>Genetic analysis of host resistance</title></titleInfo><name type="personal"><namePart type="given">B</namePart><namePart type="family">Beutler</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Beutler B, et al. Genetic analysis of host resistance: toll-like receptor signaling and immunity at large. Annu Rev Immunol 2006;24:353–389.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>353</start><end>389</end></extent></part><relatedItem type="host"><titleInfo><title>toll-like receptor signaling and immunity at large</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>353</start><end>389</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit29"><titleInfo><title>In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell‐associated antigens</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Jung</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jung S, et al. In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell‐associated antigens. Immunity 2002;17:211–220.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>211</start><end>220</end></extent></part><relatedItem type="host"><titleInfo><title>Immunity</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>211</start><end>220</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit30"><titleInfo><title>Toll‐like receptor 4‐dependent activation of dendritic cells by beta‐defensin 2</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Biragyn</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Biragyn A, et al. Toll‐like receptor 4‐dependent activation of dendritic cells by beta‐defensin 2. Science 2002;298:1025–1029.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>298</number></detail><extent unit="pages"><start>1025</start><end>1029</end></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>298</number></detail><extent unit="pages"><start>1025</start><end>1029</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit31"><titleInfo><title>High mobility group box 1 protein interacts with multiple Toll‐like receptors</title></titleInfo><name type="personal"><namePart type="given">JS</namePart><namePart type="family">Park</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Park JS, et al. High mobility group box 1 protein interacts with multiple Toll‐like receptors. Am J Physiol Cell Physiol 2006;290:C917–C924.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>290</number></detail><extent unit="pages"><start>C917</start><end>C924</end></extent></part><relatedItem type="host"><titleInfo><title>Am J Physiol Cell Physiol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>290</number></detail><extent unit="pages"><start>C917</start><end>C924</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit32"><titleInfo><title>The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia‐reperfusion</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Tsung</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tsung A, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia‐reperfusion. J Exp Med 2005;201:1135–1143.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>201</number></detail><extent unit="pages"><start>1135</start><end>1143</end></extent></part><relatedItem type="host"><titleInfo><title>J Exp Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>201</number></detail><extent unit="pages"><start>1135</start><end>1143</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit33"><titleInfo><title>High mobility group box‐1 protein induces the migration and activation of human dendritic cells and acts as an alarmin</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Yang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Q</namePart><namePart type="family">Chen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Yang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KJ</namePart><namePart type="family">Tracey</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Bustin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JJ</namePart><namePart type="family">Oppenheim</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, Oppenheim JJ. High mobility group box‐1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 2007;81:59–66.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>81</number></detail><extent unit="pages"><start>59</start><end>66</end></extent></part><relatedItem type="host"><titleInfo><title>J Leukoc Biol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>81</number></detail><extent unit="pages"><start>59</start><end>66</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit34"><titleInfo><title>Specific recognition of cruciform DNA by nuclear protein HMG1</title></titleInfo><name type="personal"><namePart type="given">ME</namePart><namePart type="family">Bianchi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Beltrame</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Paonessa</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bianchi ME, Beltrame M, Paonessa G. Specific recognition of cruciform DNA by nuclear protein HMG1. Science 1989;243:1056–1059.</note><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>243</number></detail><extent unit="pages"><start>1056</start><end>1059</end></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>243</number></detail><extent unit="pages"><start>1056</start><end>1059</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit35"><titleInfo><title>The intracellular distribution and function of the high mobility group chromosomal proteins</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Einck</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Bustin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Einck L, Bustin M. The intracellular distribution and function of the high mobility group chromosomal proteins. Exp Cell Res 1985;156:295–310.</note><part><date>1985</date><detail type="volume"><caption>vol.</caption><number>156</number></detail><extent unit="pages"><start>295</start><end>310</end></extent></part><relatedItem type="host"><titleInfo><title>Exp Cell Res</title></titleInfo><part><date>1985</date><detail type="volume"><caption>vol.</caption><number>156</number></detail><extent unit="pages"><start>295</start><end>310</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit36"><titleInfo><title>High mobility group 1 protein (HMG‐1) stimulates proinflammatory cytokine synthesis in human monocytes</title></titleInfo><name type="personal"><namePart type="given">U</namePart><namePart type="family">Andersson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Andersson U, et al. High mobility group 1 protein (HMG‐1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000;192:565–570.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>192</number></detail><extent unit="pages"><start>565</start><end>570</end></extent></part><relatedItem type="host"><titleInfo><title>J Exp Med</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>192</number></detail><extent unit="pages"><start>565</start><end>570</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit37"><titleInfo><title>Release of chromatin protein HMGB1 by necrotic cells triggers inflammation</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">Scaffidi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Misteli</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ME</namePart><namePart type="family">Bianchi</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191–195.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>418</number></detail><extent unit="pages"><start>191</start><end>195</end></extent></part><relatedItem type="host"><titleInfo><title>Nature</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>418</number></detail><extent unit="pages"><start>191</start><end>195</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit38"><titleInfo><title>Involvement of toll‐like receptors 2 and 4 in cellular activation by high mobility group box 1 protein</title></titleInfo><name type="personal"><namePart type="given">JS</namePart><namePart type="family">Park</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Park JS, et al. Involvement of toll‐like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004;279:7370–7377.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>279</number></detail><extent unit="pages"><start>7370</start><end>7377</end></extent></part><relatedItem type="host"><titleInfo><title>J Biol Chem</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>279</number></detail><extent unit="pages"><start>7370</start><end>7377</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit39"><titleInfo><title>Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells</title></titleInfo><name type="personal"><namePart type="given">IE</namePart><namePart type="family">Dumitriu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Baruah</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ME</namePart><namePart type="family">Bianchi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AA</namePart><namePart type="family">Manfredi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Rovere‐Querini</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dumitriu IE, Baruah P, Bianchi ME, Manfredi AA, Rovere‐Querini P. Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur J Immunol 2005;35:2184–2190.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>2184</start><end>2190</end></extent></part><relatedItem type="host"><titleInfo><title>Eur J Immunol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>2184</start><end>2190</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit40"><titleInfo><title>HMG‐1 as a late mediator of endotoxin lethality in mice</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Wang</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wang H, et al. HMG‐1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248–251.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>285</number></detail><extent unit="pages"><start>248</start><end>251</end></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>285</number></detail><extent unit="pages"><start>248</start><end>251</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit41"><titleInfo><title>HMGB1 is an endogenous immune adjuvant released by necrotic cells</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">Rovere‐Querini</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rovere‐Querini P, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004;5:825–830.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>825</start><end>830</end></extent></part><relatedItem type="host"><titleInfo><title>EMBO Rep</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>825</start><end>830</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit42"><titleInfo><title>Inhibitory effect of Toll‐like receptor 4 on fusion between phagosomes and endosomes/lysosomes in macrophages</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Shiratsuchi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I</namePart><namePart type="family">Watanabe</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">O</namePart><namePart type="family">Takeuchi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Akira</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Nakanishi</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shiratsuchi A, Watanabe I, Takeuchi O, Akira S, Nakanishi Y. Inhibitory effect of Toll‐like receptor 4 on fusion between phagosomes and endosomes/lysosomes in macrophages. J Immunol 2004;172:2039–2047.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>172</number></detail><extent unit="pages"><start>2039</start><end>2047</end></extent></part><relatedItem type="host"><titleInfo><title>J Immunol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>172</number></detail><extent unit="pages"><start>2039</start><end>2047</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit43"><titleInfo><title>Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Delamarre</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Couture</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I</namePart><namePart type="family">Mellman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ES</namePart><namePart type="family">Trombetta</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Delamarre L, Couture R, Mellman I, Trombetta ES. Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis. J Exp Med 2006;203:2049–2055.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>203</number></detail><extent unit="pages"><start>2049</start><end>2055</end></extent></part><relatedItem type="host"><titleInfo><title>J Exp Med</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>203</number></detail><extent unit="pages"><start>2049</start><end>2055</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit44"><titleInfo><title>Localization, quantitation, and in situ detection of specific peptide‐MHC class I complexes using a monoclonal antibody</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Porgador</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JW</namePart><namePart type="family">Yewdell</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Deng</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JR</namePart><namePart type="family">Bennink</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RN</namePart><namePart type="family">Germain</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN. Localization, quantitation, and in situ detection of specific peptide‐MHC class I complexes using a monoclonal antibody. Immunity 1997;6:715–726.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>715</start><end>726</end></extent></part><relatedItem type="host"><titleInfo><title>Immunity</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>715</start><end>726</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit45"><titleInfo><title>TLR4 mutations are associated with endotoxin hyporesponsiveness in humans</title></titleInfo><name type="personal"><namePart type="given">NC</namePart><namePart type="family">Arbour</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Arbour NC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000;25:187–191.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>187</start><end>191</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Genet</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>187</start><end>191</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit46"><titleInfo><title>Analysis of TLR4 polymorphic variants</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">Rallabhandi</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rallabhandi P, et al. Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. J Immunol 2006;177:322–332.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>177</number></detail><extent unit="pages"><start>322</start><end>332</end></extent></part><relatedItem type="host"><titleInfo><title>new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>177</number></detail><extent unit="pages"><start>322</start><end>332</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit47"><titleInfo><title>Human toll‐like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram‐negative infections</title></titleInfo><name type="personal"><namePart type="given">DM</namePart><namePart type="family">Agnese</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Agnese DM, et al. Human toll‐like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram‐negative infections. J Infect Dis 2002;186:1522–1525.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>186</number></detail><extent unit="pages"><start>1522</start><end>1525</end></extent></part><relatedItem type="host"><titleInfo><title>J Infect Dis</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>186</number></detail><extent unit="pages"><start>1522</start><end>1525</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit48"><titleInfo><title>Single nucleotide polymorphisms of Toll‐like receptors and susceptibility to infectious disease</title></titleInfo><name type="personal"><namePart type="given">NW</namePart><namePart type="family">Schroder</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RR</namePart><namePart type="family">Schumann</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Schroder NW, Schumann RR. Single nucleotide polymorphisms of Toll‐like receptors and susceptibility to infectious disease. Lancet Infect Dis 2005;5:156–164.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>156</start><end>164</end></extent></part><relatedItem type="host"><titleInfo><title>Lancet Infect Dis</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>156</start><end>164</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit49"><titleInfo><title>Relevance of mutations in the TLR4 receptor in patients with gram‐negative septic shock</title></titleInfo><name type="personal"><namePart type="given">E</namePart><namePart type="family">Lorenz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JP</namePart><namePart type="family">Mira</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KL</namePart><namePart type="family">Frees</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DA</namePart><namePart type="family">Schwartz</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the TLR4 receptor in patients with gram‐negative septic shock. Arch Intern Med 2002;162:1028–1032.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>162</number></detail><extent unit="pages"><start>1028</start><end>1032</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Intern Med</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>162</number></detail><extent unit="pages"><start>1028</start><end>1032</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit50"><titleInfo><title>Toll‐like receptor 4 genetic variation and advanced prostate cancer risk</title></titleInfo><name type="personal"><namePart type="given">I</namePart><namePart type="family">Cheng</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SJ</namePart><namePart type="family">Plummer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Casey</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JS</namePart><namePart type="family">Witte</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cheng I, Plummer SJ, Casey G, Witte JS. Toll‐like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007;16:352–355.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>352</start><end>355</end></extent></part><relatedItem type="host"><titleInfo><title>Cancer Epidemiol Biomarkers Prev</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>352</start><end>355</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit51"><titleInfo><title>Cancer; a biological approach. I. The processes of control</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Burnet</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Burnet M. Cancer; a biological approach. I. The processes of control. Br Med J 1957;1:779–786.</note><part><date>1957</date><detail type="volume"><caption>vol.</caption><number>1</number></detail><extent unit="pages"><start>779</start><end>786</end></extent></part><relatedItem type="host"><titleInfo><title>Br Med J</title></titleInfo><part><date>1957</date><detail type="volume"><caption>vol.</caption><number>1</number></detail><extent unit="pages"><start>779</start><end>786</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit52"><titleInfo><title>IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity</title></titleInfo><name type="personal"><namePart type="given">V</namePart><namePart type="family">Shankaran</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shankaran V, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107–1111.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>410</number></detail><extent unit="pages"><start>1107</start><end>1111</end></extent></part><relatedItem type="host"><titleInfo><title>Nature</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>410</number></detail><extent unit="pages"><start>1107</start><end>1111</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit53"><titleInfo><title>Novel mode of action of c‐kit tyrosine kinase inhibitors leading to NK cell‐dependent antitumor effects</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Borg</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Borg C, et al. Novel mode of action of c‐kit tyrosine kinase inhibitors leading to NK cell‐dependent antitumor effects. J Clin Invest 2004;114:379–388.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>114</number></detail><extent unit="pages"><start>379</start><end>388</end></extent></part><relatedItem type="host"><titleInfo><title>J Clin Invest</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>114</number></detail><extent unit="pages"><start>379</start><end>388</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit54"><titleInfo><title>A critical role for natural killer T cells in immunosurveillance of methylcholanthrene‐induced sarcomas</title></titleInfo><name type="personal"><namePart type="given">NY</namePart><namePart type="family">Crowe</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MJ</namePart><namePart type="family">Smyth</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DI</namePart><namePart type="family">Godfrey</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene‐induced sarcomas. J Exp Med 2002;196:119–127.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>196</number></detail><extent unit="pages"><start>119</start><end>127</end></extent></part><relatedItem type="host"><titleInfo><title>J Exp Med</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>196</number></detail><extent unit="pages"><start>119</start><end>127</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit55"><titleInfo><title>A novel dendritic cell subset involved in tumor immunosurveillance</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Taieb</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Taieb J, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 12:214–219.</note><part><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>214</start><end>219</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Med</title></titleInfo><part><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>214</start><end>219</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit56"><titleInfo><title>Therapy‐induced tumor immunosurveillance involves IFN‐producing killer dendritic cells</title></titleInfo><name type="personal"><namePart type="given">E</namePart><namePart type="family">Ullrich</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ullrich E, et al. Therapy‐induced tumor immunosurveillance involves IFN‐producing killer dendritic cells. Cancer Res 2007;67:851–853.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>851</start><end>853</end></extent></part><relatedItem type="host"><titleInfo><title>Cancer Res</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>851</start><end>853</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit57"><titleInfo><title>Cancer despite immunosurveillance</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Zitvogel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Tesniere</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Kroemer</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006;6:715–727.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>715</start><end>727</end></extent></part><relatedItem type="host"><titleInfo><title>immunoselection and immunosubversion</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>715</start><end>727</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit58"><titleInfo><title>Cell death modalities</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Galluzzi</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Galluzzi L, et al. Cell death modalities: classification and pathophysiological implications. Cell Death Differ 2007;14:1237–1243.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>1237</start><end>1243</end></extent></part><relatedItem type="host"><titleInfo><title>classification and pathophysiological implications</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>1237</start><end>1243</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit59"><titleInfo><title>Immune response against dying tumor cells</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Zitvogel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Casares</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MO</namePart><namePart type="family">Pequignot</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Chaput</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ML</namePart><namePart type="family">Albert</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Kroemer</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zitvogel L, Casares N, Pequignot MO, Chaput N, Albert ML, Kroemer G. Immune response against dying tumor cells. Adv Immunol 2004;84:131–179.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>84</number></detail><extent unit="pages"><start>131</start><end>179</end></extent></part><relatedItem type="host"><titleInfo><title>Adv Immunol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>84</number></detail><extent unit="pages"><start>131</start><end>179</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit60"><titleInfo><title>Links between innate and cognate tumor immunity</title></titleInfo><name type="personal"><namePart type="given">F</namePart><namePart type="family">Ghiringhelli</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Apetoh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Housseau</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Kroemer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Zitvogel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ghiringhelli F, Apetoh L, Housseau F, Kroemer G, Zitvogel L. Links between innate and cognate tumor immunity. Curr Opin Immunol 2007;19:224–231.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>224</start><end>231</end></extent></part><relatedItem type="host"><titleInfo><title>Curr Opin Immunol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>224</start><end>231</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit61"><titleInfo><title>Calreticulin exposure dictates the immunogenicity of cancer cell death</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Obeid</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Obeid M, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13:54–61.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>54</start><end>61</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>54</start><end>61</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit62"><titleInfo><title>Calreticulin exposure is required for the immunogenicity of gamma‐irradiation and UVC light‐induced apoptosis</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Obeid</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Obeid M, et al. Calreticulin exposure is required for the immunogenicity of gamma‐irradiation and UVC light‐induced apoptosis. Cell Death Differ 2007; Jul 27.</note><part><date>2007</date></part><relatedItem type="host"><titleInfo><title>Cell Death Differ</title></titleInfo><part><date>2007</date></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit63"><titleInfo><title>Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from ‘silent’ to immunogenic</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Obeid</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Obeid M, et al. Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from ‘silent’ to immunogenic. Cancer Res 2007;67:7941–7944.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>7941</start><end>7944</end></extent></part><relatedItem type="host"><titleInfo><title>Cancer Res</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>7941</start><end>7944</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit64"><titleInfo><title>High mobility group box protein 1</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Messmer</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Messmer D, et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 2004;173:307–313.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>173</number></detail><extent unit="pages"><start>307</start><end>313</end></extent></part><relatedItem type="host"><titleInfo><title>an endogenous signal for dendritic cell maturation and Th1 polarization</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>173</number></detail><extent unit="pages"><start>307</start><end>313</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit65"><titleInfo><title>On regulation of phagosome maturation and antigen presentation</title></titleInfo><name type="personal"><namePart type="given">JM</namePart><namePart type="family">Blander</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Medzhitov</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Blander JM, Medzhitov R. On regulation of phagosome maturation and antigen presentation. Nat Immunol 2006;7:1029–1035.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>1029</start><end>1035</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Immunol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>1029</start><end>1035</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit66"><titleInfo><title>Innate antiviral responses by means of TLR7‐mediated recognition of single‐stranded RNA</title></titleInfo><name type="personal"><namePart type="given">SS</namePart><namePart type="family">Diebold</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Kaisho</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Hemmi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Akira</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Reis e Sousa</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7‐mediated recognition of single‐stranded RNA. Science 2004;303:1529–1531.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>303</number></detail><extent unit="pages"><start>1529</start><end>1531</end></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>303</number></detail><extent unit="pages"><start>1529</start><end>1531</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit67"><titleInfo><title>Species‐specific recognition of single‐stranded RNA via toll‐like receptor 7 and 8</title></titleInfo><name type="personal"><namePart type="given">F</namePart><namePart type="family">Heil</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Heil F, et al. Species‐specific recognition of single‐stranded RNA via toll‐like receptor 7 and 8. Science 2004;303:1526–1529.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>303</number></detail><extent unit="pages"><start>1526</start><end>1529</end></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>303</number></detail><extent unit="pages"><start>1526</start><end>1529</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit68"><titleInfo><title>A Toll‐like receptor recognizes bacterial DNA</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Hemmi</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hemmi H, et al. A Toll‐like receptor recognizes bacterial DNA. Nature 2000;408:740–745.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>408</number></detail><extent unit="pages"><start>740</start><end>745</end></extent></part><relatedItem type="host"><titleInfo><title>Nature</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>408</number></detail><extent unit="pages"><start>740</start><end>745</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit69"><titleInfo><title>Toll‐like receptor 9‐dependent activation by DNA‐containing immune complexes is mediated by HMGB1 and RAGE</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Tian</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tian J, et al. Toll‐like receptor 9‐dependent activation by DNA‐containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007;8:487–496.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>487</start><end>496</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Immunol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>487</start><end>496</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit70"><titleInfo><title>A novel role for HMGB1 in TLR9‐mediated inflammatory responses to CpG‐DNA</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Ivanov</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ivanov S, et al. A novel role for HMGB1 in TLR9‐mediated inflammatory responses to CpG‐DNA. Blood 2007;110:1970–1981.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>110</number></detail><extent unit="pages"><start>1970</start><end>1981</end></extent></part><relatedItem type="host"><titleInfo><title>Blood</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>110</number></detail><extent unit="pages"><start>1970</start><end>1981</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit71"><titleInfo><title>Immunologically active autoantigens</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Marshak‐Rothstein</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">IR</namePart><namePart type="family">Rifkin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Marshak‐Rothstein A, Rifkin IR. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu Rev Immunol 2007;25:419–441.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>419</start><end>441</end></extent></part><relatedItem type="host"><titleInfo><title>the role of toll-like receptors in the development of chronic inflammatory disease</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>419</start><end>441</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit72"><titleInfo><title>Immunotherapy and chemotherapy – a practical partnership</title></titleInfo><name type="personal"><namePart type="given">RA</namePart><namePart type="family">Lake</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BW</namePart><namePart type="family">Robinson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lake RA, Robinson BW. Immunotherapy and chemotherapy – a practical partnership. Nat Rev Cancer 2005;5:397–405.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>397</start><end>405</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Rev Cancer</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>397</start><end>405</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit73"><titleInfo><title>Antivascular therapy of cancer</title></titleInfo><name type="personal"><namePart type="given">BC</namePart><namePart type="family">Baguley</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003;4:141–148.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>141</start><end>148</end></extent></part><relatedItem type="host"><titleInfo><title>DMXAA</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>141</start><end>148</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit74"><titleInfo><title>Activation of tumor‐associated macrophages by the vascular disrupting agent 5,6‐dimethylxanthenone‐4‐acetic acid induces an effective CD8+T‐cell‐mediated antitumor immune response in murine models of lung cancer and mesothelioma</title></titleInfo><name type="personal"><namePart type="given">AS</namePart><namePart type="family">Jassar</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jassar AS, et al. Activation of tumor‐associated macrophages by the vascular disrupting agent 5,6‐dimethylxanthenone‐4‐acetic acid induces an effective CD8+T‐cell‐mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res 2005;65:11752–11761.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>11752</start><end>11761</end></extent></part><relatedItem type="host"><titleInfo><title>Cancer Res</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>11752</start><end>11761</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit75"><titleInfo><title>The chemotherapeutic agent DMXAA potently and specifically activates the TBK1‐IRF‐3 signaling axis</title></titleInfo><name type="personal"><namePart type="given">ZJ</namePart><namePart type="family">Roberts</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Roberts ZJ, et al. The chemotherapeutic agent DMXAA potently and specifically activates the TBK1‐IRF‐3 signaling axis. J Exp Med 2007;204:1559–1569.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>204</number></detail><extent unit="pages"><start>1559</start><end>1569</end></extent></part><relatedItem type="host"><titleInfo><title>J Exp Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>204</number></detail><extent unit="pages"><start>1559</start><end>1569</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit76"><titleInfo><title>Bortezomib enhances dendritic cell (DC)‐mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Spisek</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Charalambous</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Mazumder</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DH</namePart><namePart type="family">Vesole</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Jagannath</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MV</namePart><namePart type="family">Dhodapkar</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)‐mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 2007;109:4839–4845.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>109</number></detail><extent unit="pages"><start>4839</start><end>4845</end></extent></part><relatedItem type="host"><titleInfo><title>therapeutic implications</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>109</number></detail><extent unit="pages"><start>4839</start><end>4845</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit77"><titleInfo><title>Toll‐like receptor interference in myeloid dendritic cells through head and neck cancer</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Frenzel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Hoffmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Brocks</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Schlenke</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Pries</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Wollenberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Frenzel H, Hoffmann B, Brocks C, Schlenke P, Pries R, Wollenberg B. Toll‐like receptor interference in myeloid dendritic cells through head and neck cancer. Anticancer Res 2006;26:4409–4413.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>4409</start><end>4413</end></extent></part><relatedItem type="host"><titleInfo><title>Anticancer Res</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>4409</start><end>4413</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit78"><titleInfo><title>Cinchonine per os</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">Genne</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">O</namePart><namePart type="family">Duchamp</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Solary</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Magnette</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JP</namePart><namePart type="family">Belon</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Chauffert</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Genne P, Duchamp O, Solary E, Magnette J, Belon JP, Chauffert B. Cinchonine per os: efficient circumvention of P-glycoprotein-mediated multidrug resistance. Anticancer Drug Des 1995;10:103–118.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>103</start><end>118</end></extent></part><relatedItem type="host"><titleInfo><title>efficient circumvention of P-glycoprotein-mediated multidrug resistance</title></titleInfo><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>103</start><end>118</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit79"><titleInfo><title>Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein</title></titleInfo><name type="personal"><namePart type="given">E</namePart><namePart type="family">Wattel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wattel E, et al. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study. Br J Haematol 1998;102:1015–1024.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>102</number></detail><extent unit="pages"><start>1015</start><end>1024</end></extent></part><relatedItem type="host"><titleInfo><title>results of a randomized study</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>102</number></detail><extent unit="pages"><start>1015</start><end>1024</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit80"><titleInfo><title>Single step high‐throughput determination of Toll‐like receptor 4 polymorphisms</title></titleInfo><name type="personal"><namePart type="given">BB</namePart><namePart type="family">Van Rijn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Roest</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Franx</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HW</namePart><namePart type="family">Bruinse</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HA</namePart><namePart type="family">Voorbij</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Van Rijn BB, Roest M, Franx A, Bruinse HW, Voorbij HA. Single step high‐throughput determination of Toll‐like receptor 4 polymorphisms. J Immunol Methods 2004;289:81–87.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>289</number></detail><extent unit="pages"><start>81</start><end>87</end></extent></part><relatedItem type="host"><titleInfo><title>J Immunol Methods</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>289</number></detail><extent unit="pages"><start>81</start><end>87</end></extent></part></relatedItem></relatedItem><identifier type="istex">6E58E70BE60E9987B65A592E6DD568CE0C05FFED</identifier><identifier type="ark">ark:/67375/WNG-F6NC73K3-P</identifier><identifier type="DOI">10.1111/j.1600-065X.2007.00573.x</identifier><identifier type="ArticleID">IMR573</identifier><accessCondition type="use and reproduction" contentType="copyright">© Wiley. All rights reserved.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-15</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-F6NC73K3-P/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E83 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000E83 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:6E58E70BE60E9987B65A592E6DD568CE0C05FFED
|texte= The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy
}}
| This area was generated with Dilib version V0.6.33. |  |